Assessment of the genotoxicity of atenolol in human peripheral blood lymphocytes: Correlation between chromosomal fragility and content of micronuclei

• Published in: Mutation research. Genetic toxicology and environmental mutagenesis 2010-01, Vol.695 (1-2), p.46-54
• Main Authors: Télez, Mercedes, Ortiz-Lastra, Eduardo, Gonzalez, Adolfo J., Flores, Piedad, Huerta, Iratxe, Ramírez, Juan M., Barasoain, Maitane, Criado, Begoña, Arrieta, Isabel
• Format: Article
• Language: English
• Subjects: Antihypertensives; Biological and medical sciences; Chromosomes; Content of micronuclei; Correlation analysis; Fluorescence in situ hybridization; Fragile sites; Fundamental and applied biological sciences. Psychology; Genetics of eukaryotes. Biological and molecular evolution; Genotoxicity; Hypertension; Lymphocytes; Medical sciences; Studies; Toxicity; Toxicology
• ISSN: 1383-5718; 1879-3592
• DOI: 10.1016/j.mrgentox.2009.02.015

The antihypertensive drug atenolol was found to induce chromosome loss, detected as micronuclei in the peripheral lymphocytes of treated patients. The fundamental question which chromosomes the micronuclei were derived from remains to be answered. Analysis of structural chromosomal aberrations (CAs) and expression of fragile sites (FS) were pursued in this study. They revealed a significantly higher incidence of chromosomal aberrations (chromatid and chromosome breaks) in patients compared with controls, where 10 FS emerged as specific. Also, the band 17q12–21, where known fragile sites have not been reported, was only expressed in atenolol-treated patients. Fluorescence in situ hybridization using chromosome-specific probes revealed the preferential involvement of chromosomes 7, 11, 17 and X in the micronuclei (MN) of patients. The results also suggest a correlation between chromosomal fragility and content of MN, and support the findings for a linkage between hypertension and a locus on chromosome 17.